Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation

ONAT, A.; Can, Günay; HERGENC, G.; YAZICI, M.; KARABULUT, A.; ALBAYRAK, S.

doi:10.1038/sj.ijo.0803552

Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation

ONAT A., Can G., HERGENC G., YAZICI M., KARABULUT A., ALBAYRAK S.

INTERNATIONAL JOURNAL OF OBESITY, cilt.31, sa.7, ss.1119-1125, 2007 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 31 Sayı: 7
Basım Tarihi: 2007
Doi Numarası: 10.1038/sj.ijo.0803552
Dergi Adı: INTERNATIONAL JOURNAL OF OBESITY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1119-1125
İstanbul Üniversitesi Adresli: Hayır

Özet

Objectives: To investigate the role of serum apolipoprotein (apo) B levels in predicting metabolic syndrome (MS), hypertension, atherogenic dyslipidemia and type II diabetes.